Summary
- Profile Type
- Technology offer
- POD Reference
- TOES20230608005
- Term of Validity
- 8 June 2023 - 7 June 2025
- Company's Country
- Spain
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The Foundation for Biosanitary Research and Innovation of the Principality of Asturias (FINBA) (Spain) has applied for the patent of an invention related to a biomarker (GARP, Golgi Associated Retrograde Protein Complex) and a method for predicting or forecasting response to cancer treatment, preferably to the treatment of sarcomas. They are looking for a biomedical/biotechnological company interested in a license and/or collaboration agreement to develop and exploit this asset.
- Full Description
-
Currently, treatment of bone sarcoma is multimodal and consists of a combination of surgery and/or chemotherapy. The poor prognosis of sarcoma correlates with resistance to conventional chemotherapy and radiotherapy.
Patients whose sarcomas express GARP have a significantly poor 5-year survival. In addition, those osteosarcoma lines with high GARP expression show greater resistance to drug- and radiation-induced cell death.
In contrast, the prognosis of patients with low GARP expression is better.
GARP represents a new therapeutic target for the treatment of sarcoma, possibly in combination with traditional chemotherapy drugs and radiotherapy.
In terms of its effect, GARP activates TGFβ factor, a key mediator in cancer. Currently available TGFβ (Transforming Growth Factor β) antagonists do not distinguish between physiological and disease-induced TGFβ activation, resulting in a high risk of side effects. Since GARP expression is more restricted than that of TGFβ, its use as a therapeutic target would imply a safer and more efficient blockade of the pro-cancer effect of TGFβ. - Advantages and Innovations
-
The innovative aspects of the invention are related to the following points:
- Inhibiting GARP function would have a dual benefit: on the one hand, it would possess antiproliferative activity, and on the other hand, it would increase the sensitivity of cancer cells to chemotherapy as well as radiotherapy.
- GARP expression levels can identify those patients with a worse prognosis and response to chemotherapy. - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
- Biomedical/Biotechnological company interested in a license and/or a collaboration agreement to develop and exploit this asset.
- Type and Size of Partner
- SME 50 - 249
- University
- SME 11-49
- R&D Institution
- SME <=10
- Big company
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06002007 - In vitro Testing, Trials
- 06003002 - Gene Expression, Proteome Research
- 06001005 - Diagnostics, Diagnosis
- 06001012 - Medical Research
- 06002002 - Cellular and Molecular Biology
- Market keywords
- 05001005 - Molecular diagnosis
- 05001002 - In-vitro diagnostics
- Sector Groups Involved
- Health
- Targeted countries
- All countries